论文部分内容阅读
目的由于晚期肺鳞癌的早期症状和体征均不明显,很多患者没有及时确诊及治疗,失去了手术机会,化疗是晚期患者的主要治疗方式,目的是延长生存期,提高生活质量。本研究探讨分析吉西他滨联合奈达铂方案治疗晚期肺鳞癌的临床疗效和安全性。方法选取2015-10-08-2016-12-31海口市人民医院收治的晚期肺鳞癌患者184例,按照随机数字表法将患者分为对照组和观察组各92例。对照组患者接受多西他赛联合顺铂的化疗方案,观察组患者接受吉西他滨联合奈达铂的治疗方案。在患者接受2个周期治疗后评估治疗的近期疗效和不良反应发生情况,并进行两组间比较。结果两组患者的近期疗效比较,差异无统计学意义,χ~2=0.113,P=0.945。观察组和对照组总缓解率分别为40.22%(37/92)和39.13%(32/92),差异无统计学意义,χ~2=0.023,P=0.880;观察组和对照组疾病控制率分别为65.22%(60/92)和66.30%(61/92),差异无统计学意义,χ~2=0.024,P=0.877。两组患者化疗期间不良反应比较,观察组患者白细胞下降(χ~2=31.745,P<0.001)、红细胞下降(χ~2=11.280,P=0.001)和恶心呕吐(χ~2=11.290,P=0.001)的发生率显著小于对照组,差异均有统计学意义。但两组患者血小板下降(χ~2=0.035,P=0.851)、肝功能受损(χ~2=2.421,P=0.120)、肾功能受损(χ~2=0.464,P=0.496)和脱发(χ~2=1.517,P=0.218)的发生率差异无统计学意义。结论吉西他滨联合奈达铂方案对晚期肺鳞癌的疗效与多西他赛联合顺铂方案相当,不良反应发生率低,安全性更高,值得进一步推广运用。
The purpose of the early lung squamous cell carcinoma of the early symptoms and signs are not obvious, many patients without timely diagnosis and treatment, lost the chance of surgery, chemotherapy is the main treatment for patients with advanced, the purpose is to extend the survival and improve quality of life. This study was to investigate the clinical efficacy and safety of gemcitabine combined with nedaplatin regimen in the treatment of advanced squamous cell carcinoma of the lung. METHODS: A total of 184 patients with advanced squamous cell carcinoma of the lung admitted to Haikou People’s Hospital were enrolled in this study. The patients were divided into control group and observation group according to random number table method. Patients in the control group received chemotherapy for docetaxel plus cisplatin, and patients in the observation group received gemcitabine plus nedaplatin. The patients were treated with two cycles after treatment to assess the short-term efficacy of treatment and adverse reactions, and the comparison between the two groups. Results There was no significant difference in short-term curative effect between the two groups (χ ~ 2 = 0.113, P = 0.945). The total remission rate of the observation group and the control group were 40.22% (37/92) and 39.13% (32/92) respectively, with no significant difference (χ ~ 2 = 0.023, P = 0.880). The disease control rates 65.22% (60/92) and 66.30% (61/92) respectively, the difference was not statistically significant (χ ~ 2 = 0.024, P = 0.877). In the two groups of patients, the leukopenia (χ ~ 2 = 31.745, P <0.001), erythrocyte decline (χ ~ 2 = 11.280, P = 0.001) and nausea and vomiting (χ ~ 2 = 11.290, P = 0.001) was significantly lower than the control group, the difference was statistically significant. However, the platelet count (χ ~ 2 = 0.035, P = 0.851), impaired liver function (χ ~ 2 = 2.421, P = 0.120) and impaired renal function Hair loss (χ ~ 2 = 1.517, P = 0.218) no significant difference in the incidence. Conclusion The combination of gemcitabine and nedaplatin is effective in the treatment of advanced squamous cell carcinoma of the lung. Compared with docetaxel and cisplatin, the combination of gemcitabine and nedaplatin has a lower incidence of adverse reactions and higher safety. It is worth further promotion and application.